We develop ADCs and radioligands, leveraging our conjugation platform. We create new treatments ofefring hope to patients that suffer from aggressive cancer with poor prognosis.
Products, services, technology
The CIS Biopharma AG pipeline, developed by the team, comprises:
CBO-001, a full-length antibody targeting L1CAM / CD-171
CBO-002, a nanobody targeting B7-H3 / CD-276
CBO-003, a polymer-based drug-carrier technology platform
Cooperation possibilities
We collaborate with patient organizations, clinics, physicians, scientists and financial partners to advance breakthrough technology in cancer therapy.
- http://www.cis-pharma.com
- +41 61 935 53 23
- christoph.schaefer@cis-pharma.com
- Franziska Strütt
Some insights
- Patient Organizations
- Physicians
- Pharma
- BioTech
- Institutional Investors
We develop ADCs and radioligands to treat cancer patients more effectively.
We are proud to be part of a larger community of scientists and physicians committed to fighting cancer. It is a great pleasure to collaborate with passionate experts,
Dr. Mary-Claire King is a geneticist who discovered the BRCA1 gene, which is associated with an increased risk of breast and ovarian cancer. Her groundbreaking research has had a significant impact on the understanding and treatment of these cancers.
We help cancer patients in fighting their disease and offer them a better quality of life during that combat.